Clinical Trial Update: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial update reports safety and efficacy findings for ALLO-605, an anti-BCMA allogeneic CAR T-cell therapy, in relapsed/refractory multiple myeloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ALLO-605 (anti-BCMA allogeneic CAR T cell therapy)

Snippet

Sponsor: Allogene Therapeutics | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED